Statements (65)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:administered_by |
injection
|
| gptkbp:advocacy |
required before administration
supported by various health organizations |
| gptkbp:age_group |
9 to 26 years
|
| gptkbp:approves |
gptkb:2006
gptkb:U._S._Food_and_Drug_Administration_(FDA) |
| gptkbp:associated_with |
increased screening rates
decreased HPV prevalence |
| gptkbp:available_on |
single-dose vials
multi-dose vials |
| gptkbp:clinical_trial |
conducted for safety and efficacy
|
| gptkbp:community_health |
reduces HPV-related cancers
reduces incidence of genital warts significant reduction in HPV-related morbidity and mortality |
| gptkbp:contains |
recombinant HPV proteins
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
|
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:distribution |
available worldwide
|
| gptkbp:dosage_form |
not routinely recommended
three doses |
| gptkbp:educational_resources |
available for healthcare providers and patients
|
| https://www.w3.org/2000/01/rdf-schema#label |
Gardasil
|
| gptkbp:influenced_by |
gptkb:healthcare_professionals
public health policies government health initiatives vaccine advocacy groups |
| gptkbp:introduced_in |
multiple countries
|
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
high efficacy in preventing HPV-related diseases
|
| gptkbp:is_recommended_for |
prevention of cervical cancer
prevention of anal cancer prevention of genital warts prevention of oropharyngeal cancer |
| gptkbp:is_vulnerable_to |
varies by region
quadrivalent addressed through education ongoing post-marketing surveillance involved extensive research 0, 2, and 6 months improved in many countries nonavalent |
| gptkbp:marketed_as |
gptkb:Gardasil_9
|
| gptkbp:part_of |
routine immunization schedule
|
| gptkbp:price |
varies by country
|
| gptkbp:provides_guidance_on |
recommended by health organizations
|
| gptkbp:public_awareness |
conducted to promote vaccination
|
| gptkbp:research_continues |
to evaluate long-term effects
|
| gptkbp:shelf_life |
up to 36 months
|
| gptkbp:side_effect |
fatigue
headache nausea fever pain at injection site monitored by health authorities |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
gptkb:human_papillomavirus_(HPV)
|
| gptkbp:vaccine_approval_process |
involves clinical trials and regulatory review
|
| gptkbp:bfsParent |
gptkb:human_papillomavirus
gptkb:Merck_Sharp_&_Dohme_Corp. gptkb:human_papillomavirus_(HPV)_types_16_and_18 gptkb:Merck_&_Co.,_Inc. gptkb:Merck_Research_Laboratories gptkb:Merck_Vaccines |
| gptkbp:bfsLayer |
6
|